GSK Sues Over Genentech Antibody Patent

By Richard Vanderford

Law360, New York (October 08, 2009, 6:04 PM ET) -- GlaxoSmithKline has filed a suit in federal court challenging the validity of a patent belonging to rival Genentech Inc. as it prepares to release a cancer drug.

GSK filed a complaint Thursday in the U.S. District Court for the Southern District of Florida, asking for a declaratory judgment that Genentech's “Cabilly” patent is invalid and not infringed by GSK's Arzerra, the brand name of the drug ofatumumab.

GSK and partner GenMab submitted a biologics license application to U.S. Food and Drug Administration in January, asking permission...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles